Company

PALVELLA

PALVELLA THERAPEUTICS, INC.

PVLA pharma USA

Quick answer

PALVELLA is a pharma company (PVLA) headquartered in WAYNE, PA, USA with 7 tracked pipeline programs.

Pipeline (7)

PTX-022

Pachyonychia Congenita

Phase 3 · small_molecule · active

3 trials project

QTORIN 3.9% Rapamycin Anhydrous Gel

Microcystic Lymphatic Malformation

Phase 3 · small_molecule · active

1 trials project

QTORIN 3.9% rapamycin anhydrous gel

Pachyonychia Congenita

Phase 3 · small_molecule · completed

1 trials project

PTX-022

BCCs in Gorlin Syndrome Patients

Phase 2 · small_molecule · completed

1 trials project

PTX-022

Microcystic Lymphatic Malformation

Phase 2 · small_molecule · completed

1 trials project

PTX-022

Angiokeratomas

Phase 2 · small_molecule · active

1 trials project

QTORIN 3.9% rapamycin anhydrous gel

Cutaneous Venous Malformations

Phase 2 · small_molecule · active

Patents (8)

US 12329748

Anhydrous compositions of mTOR inhibitors and methods of use

Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12268673

Anhydrous compositions of mTOR inhibitors and methods of use

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11679101

Anhydrous compositions of mTOR inhibitors and methods of use

Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11617742

Methods of treating keratin hyperproliferation disorders using mTOR inhibitors

Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11135204

Anhydrous compositions of mTOR inhibitors and methods of use

Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11000513

Anhydrous compositions of mTOR inhibitors and methods of use

Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10722499

Anyhydrous compositions of mTOR inhibitors and methods of use

Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10172789

Compositions for transdermal delivery of mTOR inhibitors

Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026